TOKYO--(BUSINESS WIRE)--July 25, 2006--Shanghai Genomics Inc, the China-based affiliate of GNI and one of China's leading biotech companies, today announced an agreement to collaborate on a drug discovery research project with Centocor, Inc. a U.S. based biopharmaceutical company and world leader in monoclonal antibody production and technology. The collaboration, which will involve biological research aimed at understanding inflammatory signaling pathways, will initially last for a period of one and a half years.
